Products for Research Use Only

Recombinant Human EPO

CAT: 0171-Z101435Size: 50 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0171-Z101435Size:50 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary, endothelial, and interstitial cells of the kidney. Approximately 10-15% of the total amount of EPO comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of EPO is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behaviour of EPO in vivo. Non-glycosylated Epo has an extremely short biological half life. Recombinant Human EPO is a glycosylated protein that runs at approximately 35 kDa owing to its glycosylation.
CAS Number
9000-83-3
Gene Name
EPO
Gene Aliases
Erythropoietin
Recombinant Human Erythropoietin-Alpha (EPO)
Gene ID
2056
Accession Number
P01588
Organism
Human
Source
CHO
Concentration
<1.0 EU/μg of recombinant protein as determined by the LAL method
Purity
>95% as determined by SDS-PAGE
Solubility
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Function
Activity was determined by the dose-dependent proliferation assay using a factor-dependent human erythroleukemic cell line TF-1 and was found to be less than 0.2ng/ml
Molecular Weight
20
Shipping Conditions
Ambient Temperature
Storage Conditions
The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Appearance
Lyophilized Powder
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS (pH 7)